علاج الالتهاب الرئوي الشديد المكتسب من المجتمع في البالغين المستشفيين بدون عوامل خطر MRSA أو Pseudomonas aeruginosa

References

In inpatient adults with severe CAP without risk factors for MRSA or P. aeruginosa, we recommend (note, specific agents and doses are the same as 9.1):

Validated definition includes either one major criterion or three or more minor criteria.

a β-lactam plus a macrolide (strong recommendation, moderate quality of evidence); or a β-lactam plus a respiratory fluoroquinolone (strong recommendation, low quality of evidence).

We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).

As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients.

DOI: 10.1164/rccm.201908-1581ST